Phase 3 Readout

NGNE: Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy,

Name: Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy,
Start: 2029-12-01
End: 2029-12-01

December 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2029
Company: Neurogene Inc. (NGNE)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy,

December 1, 2029

NGNE overview →

Company: Neurogene Inc. (NGNE)
Indication: Rett Syndrome